Who makes Qinggongshoutao Bolus?

Qinggongshoutao Bolus is developed by Dongzhimen Hospital, Beijing.

What development phase is Qinggongshoutao Bolus in?

Qinggongshoutao Bolus is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Qinggongshoutao Bolus

Dongzhimen Hospital, Beijing · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Qinggongshoutao Bolus
Also known as	Ginkgo biloba also named Egb761 or Ginaton
Sponsor	Dongzhimen Hospital, Beijing
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Qinggongshoutao Bolus CI brief — competitive landscape report
Qinggongshoutao Bolus updates RSS · CI watch RSS
Dongzhimen Hospital, Beijing portfolio CI